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ABSTRACT 
 
Background and Objectives: Association between Mycoplasma pneumoniae infection and increased risk for brain stroke 
has been well understood. Hence, the value of serologic tests for assessing causative relationship between this infection and 
brain stroke seems to be high. The present study aimed to determine serum level of anti-Mycoplasma pneumoniae antibodies 
in patients with brain stroke and to compare it with non-stroke patients.
Materials and Methods: This cross-sectional study was performed on 97 consecutive ischemic stroke patients and 97 sex 
and age-matched non-stroke patients. Quantitative enzyme-linked immunosorbent assay (ELISA) was established to mea-
sure the levels of anti-Mycoplasma pneumoniae IgG and IgM antibodies.
Results: Regarding the level of anti-Mycoplasma pneumoniae IgM, the titer of this marker was positive in 4.1% of patients 
with ischemic stroke, while none of the subjects in control group had positive titer for this antibody (OR = 1.043, 95%CI: 
1.001 – 1.087, p = 0.043). The rate of positivity for anti-Mycoplasma pneumoniae IgG in ischemic stroke patients was signifi-
cantly higher than in the control group (28.5% versus 13.4%, p = 0.031). Odds ratio for exposure to M. pneumoniae was 2.24 
times of the control subjects. The level of anti-Mycoplasma pneumoniae IgM was independent to both sex and age variables 
in patients group (p = 0.77). The level of anti-Mycoplasma pneumoniae IgG did not depend on subjects’ gender in control 
group, but was significantly higher in men compared with women in patients group. 
Conclusion: A high level of anti-Mycoplasma pneumoniae IgM and IgG antibodies indicate a significant association of M. 
pneumoniae infection and history of this infection with increased risk for ischemic stroke. 
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INTRODUCTION
One of the possible risk factors causing stroke has 
considered to be infections (1, 2). Chlamydophy-
la pneumoniae, is one of the respiratory pathogen 
which has been connected to atherosclerotic vascular 
diseases (3, 4).  Mycoplasma  pneumoniae, is another 
micro-organism which has the same epidemiological 
behaviour that after respiratory tract infection can 
bring extra pulmonary symptoms and chronic se-
quelae (5, 6).
 There has been growing evidence showing that in 
spite of the main presentation of M.  pneumoniae in-
fection which cause respiratory problems, it also has 
the ability in producing  a wide range of extra pul-
monary manifestations including neurologic, cardi-
ac, dermatologic, musculoskeletal, hematologic, and 
gastrointestinal (7).
The most common and life-threatening extrapul-
monary complications of Mycoplasma pneumoniae 
infection are central nervous system (CNS) mani-
festations (8, 9). The prevalence of M. pneumoni-
ae-associated neurologic complications is not clear. 
Among patients with neurologic syndromes, M. 
pneumoniae association has been shown in 5% to 
10% of cases (10, 11).
Various epidemiological, serological, and even ge-
netic studies could show an association between M. 
pneumoniae infection and increased risk for neuro-
logical complications (12-16). Even, exposure to M. 
pneumoniae infection has been shown to adversely 
affect prognosis of these affected patients (17). Ac-
cording to some reports, neurological defects may 
occur in 0.1% of M. pneumoniae infections that is 
mostly manifested by neurological infections or in-
flammatory conditions such as meningitis, enceph-
alitis, cerebellar syndromes, myelitis, and polyrad-
iculitis (18). However, an unusual manifestation of 
M. pneumoniae infection is brain stroke due to the 
potential impact of this infection on occurring vas-
culopathies (19). Because the clinical symptoms and 
imaging evidences of brain stroke due to M. pneumo-
niae infection is not specific, the use of more accurate 
diagnostic test can help the clinicians to early diagno-
sis of stroke caused by this infection and lead to prop-
er selection of the best therapeutic modality against 
this infection (20). In this regard, the serological 
test is one way to detect the origin of infection in its 
acute or chronic phases of infection.In fact, markedly 
elevation of serum antibody titers to M. pneumoniae 
and the detection of specific IgM and IgG antibodies 
against this microorganism can be one of the sero-
logical diagnostic choice to confirm brain stroke spe-
cifically caused by Mycoplasma  pneumoniae (21). 
Furthermore, applying specific serological test along 
with genetically assessing the presence of M. pneu-
moniae DNA may result in obtaining the highest ac-
curacy for detecting infection in brain stroke patients 
(22). Our case-control study was the prospectively to 
examine for the seroprevalence of M. pneumoniae, 
and its relationship with acute stroke.
 
MATERIALS AND METHODS
 
   Study population. This epidemiological cross-sec-
tional study was performed on 97 consecutive 
patients aged 45 to 80 years referred to Shoha-
da-e-Ashaayer hospital in Khorramabad, Iran be-
tween August 2012 to August 2013 with clinical 
manifestations and ischemic lesions in brain CT that 
finally diagnosed as ischemic cerebrovascular acci-
dents. Those with rheumatologic or inflammatory 
disorders such as lupus, scleroderma, Sjogren's syn-
drome or vasculitis were not included into this sur-
vey. Also, 97 sex, and age-matched subjects without 
any evidences of cerebrovascular diseases were se-
lected from hospitalized patients in internal wards or 
outpatients referred to laboratory of hospital as the 
control. Baseline characteristics and clinical data of 
study participants were collected by face to face in-
terviewing in the presence the patient's bedside.
  
Study measurements. The results of laboratory 
parameters including fasting blood sugar and lipid 
profile as well as blood pressure measures were also 
collected from recorded hospital files. For all patients 
fasting blood sugar, cholesterol, triglyceride, Low 
density lipoprotein and High density lipoprotein 
measured. After the implementation and control of 
the CT images and taking informed consent to par-
ticipate in the project, 0.5 ml of serum was extracted, 
centrifuged, and transferred into micro-tubes that 
were kept frozen at –20°C until antibodies determi-
nation. Quantitative enzyme-linked immunosorbent 
assays (ELISAs) were established to measure the lev-
els of anti-M. pneumoniae IgG and IgM antibodies 
using M. pneumoniae IgG ElISA and M. pneumoni-
ae IgM ElISA kits (IBL, Germany). The assay was 
considered positive if the level of IgM and IgG ≥ 1.1 
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mg and was considered borderline if the level of anti-
bodies ranged 0.8 to 1.1 mg. For borderline samples, 
the test was repeated and if the titer was ranged in 
the borderline ranges, it was considered as negative. 
Statistical analysis. Results were presented as 
mean ± standard deviation (SD) for quantitative vari-
ables and were summarized by absolute frequencies 
and percentages for categorical variables. Categor-
ical variables were compared using chi-square test 
or Fisher's exact test when more than 20% of cells 
with expected count of less than 5 were observed. 
Quantitative variables were also compared with 
Mann- Whitney U test. Statistical significance was 
determined as a p value of ≤ 0.05. All statistical anal-
ysis was performed using SPSS software (version 
19.0, SPSS Inc., Chicago, Illinois).
 
RESULTS
  Overall, 97 patients with ischemic stroke and 97 
Table 1. Baseline characteristics and clinical data of patients and controls
P-value
0.14
0.15
0.43
0.60
0.82
0.57
0.55
1.00
0.74
0.06
0.81
0.86
0.60
0.17
0.49
0.78
0.43
0.33
0.44
0.32
0.68
Control group (n = 97)
46 (47.4)
51 (52.6)
67.2 ± 8.9
12 (12.4)
37 (38.1)
48 (49.5)
6 (6.8)
33 (34.5)
7 (7.1)
21 (21.4)
9 (9.5)
15 (15.5)
3 (3.6)
29 (29.9)
48 (48.5)
6 (6.2)
9 (9.3)
0 (0.0)
7 (7.2)
116.54 ± 37.8
189.1 ± 61.1
156.36 ± 47.5
117.13 ± 77.7
51.1 ± 27.2
Patients group (n = 97)
36 (37.1)
61 (62.9)
69.1 ± 9.3
7 (7.2)
36 (37.1)
54 (55.7)
8 (8.3)
31 (32.4)
5 (5.4)
17 (17.5)
9 (9.5)
17 (17.5)
10 (10.8)
27 (27.8)
50 (50.5)
8 (8.2)
4 (4.1)
2 (2.1)
6 (6.2)
123.23 ± 56.5
197.5 ± 55.1
169.78 ± 68.2
105.5 ± 36.5
54.2 ± 33.4
        Characteristics
Male
Female
45 – 54 years
55 – 69 years
≥ 70 years
Hyperlipidemia
Hypertension
Diabetes mellitus
Hyperlipidemia+hypertension
Diabetes + hypertension
Hyperlipidemia + hypertension + diabetes
Hypertension + heart failure
Unemployed
Housekeeper
Farmer
Worker
Retired
Employed
Fasting blood sugar, mg/dl
Total cholesterol, mg/dl
Triglyceride, mg/dl
Low density lipoprotein, mg/dl
High density lipoprotein, mg/dl
Gender
Mean age, year
Age group
Medical history
Occupational status
Laboratory indices
healthy controls were assessed with respect to the 
levels of anti-M. pneumoniae antibodies.  The two 
groups were matched for mean age (69.1 ± 9.3 years 
versus 67.2 ± 8.9 years, p = 0.15), female gender distri-
bution (62.9% versus 52.6%, p = 0.14), and also occu-
pational state (Table 1). There was also no difference 
in the prevalence rates of cardiovascular risk factors 
between the patients and the control including hyper-
lipidemia (8.3% versus 6.8%, p = 0.446), hyperten-
sion (32.4% versus 34.5%, p = 779), diabetes mellitus 
(5.4% versus 7.1%, p = 0.06), and also in combination 
of these risk profiles (Table 1). Also, the mean serum 
levels of biomarkers including fasting blood sugar, 
and lipid profile were similar in both study groups.
   Regarding the level of anti-Mycoplasma pneumoni-
ae IgM, the titer of this marker was positive in 4.1% 
of patients with ischemic stroke, while none of the 
subjects in control group had positive titer for this an-
tibody (OR = 1.043, 95%CI: 1.001 – 1.087, p = 0.043). 
Moreover, the rate of positivity for anti-Mycoplas-
ma pneumoniae IgG in ischemic stroke patients was 
significantly higher than in the control group (28.5% 
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versus 13.4%, p = 0.031). In this regard, odds ratio 
for exposure to M. pneumoniae was 2.24 times of the 
control subjects (OR = 2.24, 95%CI: 1.070 – 4.700, 
P = 0.031) (Table 2). The level of anti-Mycoplasma 
pneumoniae IgM was independent to both sex and 
age variables in patients group that the titer for IgM 
antibody was positive in none of the patients in the 
age range 45 to 54 years, in 5.6% of patients in the 
age range 55 to 69 years and in 3.7% of patients older 
than 69 years (p = 77). Also, 8.3% of affected men 
and 1.6% of affected women had positive titer for an-
ti-Mycoplasma pneumoniae IgM (p = 0.14). As shown 
in Table 3, the level of anti-Mycoplasma pneumoniae 
IgG did not depend on subjects’ gender in control 
group, but was significantly higher in men compared 
with women in patients group. This table also shows 
that the level of anti-Mycoplasma pneumoniae IgG is 
independent to age distribution in both patients and 
controls groups.
DISCUSSION
   Because of important role of M. pneumoniae in cere-
brovascular complications measuring of antibodies in 
serum or cerebrospinal fluid is highly valuable in di-
agnosis of this infection and its related neurological 
complications. The presents study found a significant 
difference in the serum level of both anti-Mycoplas-
ma pneumoniae IgM and IgG antibodies between the 
patients with brain stroke and non-stroke individuals 
who referred to hospital because of other complaints. 
In this study, odds ratio for exposure to M. pneumo-
niae was 2.24 times in brain stroke group than in the 
control subjects indicating an increased risk for occur-
rence of ischemic brain stroke and M. pneumoniae. 
Because the levels of both types of acute and chron-
ic phase antibodies were higher in patients group, it 
seems that the risk for brain stroke in those patients 
with the previous history of M. pneumoniae infection 
can be even increased. In our study, difference in the 
seroprevalence rate of antibodies between the patients 
and the controls was significant (p=0.031 and p = 
0.043 for IgG and IgM). 
    In the study of Ngeh and colleagues, the seroprev-
alence of M. pneumoniae IgG in the stroke were 61% 
that was considerably higher than in our survey. Using 
a logistic regression statistical model, adjusting for 
cardiovascular risk factors, the odds ratios of having 
a stroke or in relation to M. pneumoniae IgG in their 
study was 1.32 which is lower than that obtained in our 
study. One of the main reasons for explaining the con-
tradictory results of the present study and above-men-
tioned study may be the different employed age sub-
groups so Ngeh and colleagues focused on the older 
population (23). In another study conducted by Min 
et al. the serum level of M. pneumoniae acute phase 
antibody was significantly increased simultaneously 
MARyAM ROHAM ET AL .                                                                                                         
   386           IRAN. J. MICROBIOL.  Volume 8 Number 6 (December 2016) 383-388  
Table 2. Seroprevalence of M. pneumoniae antibody in cases and controls
Anti-Mycoplasma antibodies
Ig M
Ig G
Groups
Patients (sign of ischemia in brain CT scan)
Control group
Patients (sign of ischemia in brain CT scan)
Control group
Positive (%)
4(4.1)
0(0)
25(28.1)
13(13.4)
Negative (%)
93(95.9)
97(100)
72(74.2)
84(86.6)
P. value
0.043
0.031
OR
1.043
2.24
CI
1.001-1.087
1.070-4.700
Table 3. The positive titer for the level of anti-Mycoplasma pneumoniae IgG
Control group (n = 97)
6 (13.0)
7 (13.7)
0.92
2 (16.7)
5 (13.5)
6 (12.5)
0.94
Patients group (n = 97)
13 (36.1)
12 (19.7)
0.047
2 (28.6)
7 (19.4)
16 (29.6)
0.54
Male
Female
p-value
45 – 54 years
55 – 69 years
≥ 70 years
p-value
Characteristics
Gender
Age groups
http://ijm.tums.ac.ir
with the appearance of neurological manifestations 
in the patients referred with hemiparesis and facial 
nerve paralysis. In their study, the level of antibody 
increased in both serum and cerebrospinal fluid. Ac-
cording to this fact that the changes in antimicrobial 
antibodies in cerebrospinal fluid can be more specif-
ic than in the serum, the measurement of acute and 
chronic phase antibodies in cerebrospinal fluid lead-
ing higher diagnostic value (24).
   In another study by Chiang CH et al. it was found 
that subjects with M. pneumoniae infection were sig-
nificantly associated with increased risk of ischemic 
stroke compared with controls (1.10% versus 0.72%, 
respectively; P 0.01) (19).
   Another important result in our study was that el-
evation of anti-Mycoplasma pneumoniae antibody is 
independent to patients’ age; however this elevation 
may be more occurred in men than in women empha-
sizing higher risk for cerebrovascular accidents fol-
lowing M.  pneumoniae infection in men than in wom-
en. Also, numerically, but not significantly, the rate of 
seropositivity was higher in advanced ages. Tuuminen 
et al. could show an association between the rate of 
seropositivity and patients’ age in those who suffered 
brain stroke (25). In another study Taghizade et al. the 
relationship between seropositivity rate M. pneumo-
niae antibodies and gender in patient with acute myo-
cardial infarction remained insignificant (26). It seems 
that the higher rate of brain stroke caused by M. pneu-
moniae infection in men than in women may be due 
to higher socially and occupationally exposing this in-
fection in men compared with women. In this regard, 
the gender difference in the rate of brain stroke related 
to M. pneumoniae infection should be more assessed 
in larger population-based studies. 
 Other effects of Mycoplasma can be seen in re-
searches conducted in another articles. Among these 
we can mention two inter-related articles conducted 
by Golmohamadi and Ataee. They concluded that M. 
pneumoniae, Mycoplasma hominis, and Mycoplasma 
arthritidis have increased in RA patients (27, 28). 
Another study carried out on women in Albania with 
infertility and abortion showed another effect of My-
coplasma hominis (29).  
  In conclusion, a higher level of anti-Mycoplasma 
pneumoniae acute and chronic phase antibodies is 
detectable in patients with ischemic stroke than in 
non-stroke patients. On the other hand, high level 
of anti-Mycoplasma pneumoniae IgM and IgG anti-
bodies indicate a significant association between M. 
pneumoniae infection and history of this infection and 
increased risk for ischemic stroke.
   According to the results that obtained in recent stud-
ies clinicians should be aware of this potential associ-
ation between M. pneumoniae infection and several 
CNS manifestations, when confronted with  nervous 
symptoms of unknown cause especially if the patient’s 
history includes respiratory manifestation. 
  They should attempt to establish this association 
whenever possible with the aid of molecular or sero-
logical techniques . Further studies may be required to 
clarify and define the meticulous role of M. pneumoni-
ae infection as a potential factor in the pathogenesis of 
ischemic stroke, in all age groups, and in different race 
populations. A better understanding of the pathogene-
sis of such manifestations will not only help the cli-
nician diagnose and treat this rare entity but may also 
lead to new insight into complex neurological injury 
and its potential association with infectious agents.
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